---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-059936"
form_type: "8-K"
ticker: "PLUR"
cik: "0001158780"
company_name: "Pluri Inc."
filed_at: "2022-09-29T23:59:59+00:00"
generated_at: "2026-06-23T06:37:53.631693+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pluri signs biologics API collaboration, cuts cash burn 30%, holds $56M cash

## Summary
- New collaboration with European API manufacturer for liver/gastro drugs; revenue expected in coming months.
- Annual cash burn reduced ~30% from $36M to ~$24M; $56M cash at June 30, 2022.
- Plurinuva JV with Tnuva: first cultivated meat product in development; proof of concept this year, launch 2023.
- Second tech collaboration after Tnuva; targets $366B biologics market, growing to $720B by 2030.

## SEC filing metadata
- accession: 0001213900-22-059936
- form_type: 8-K
- ticker: PLUR
- cik: 0001158780
- company_name: Pluri Inc.
- filed_at: 2022-09-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1158780/000121390022059936/0001213900-22-059936-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1158780/000121390022059936/ea166516-8k_pluriinc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-059936
- JSON: https://secwatch.observer/filing/0001213900-22-059936.json
- Plain text: https://secwatch.observer/filing/0001213900-22-059936.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.